Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utomilumab + Mogamulizumab in Advanced Solid Tumors
NCT02444793Phase 1Terminated
- Sponsor
- Pfizer
- Start
- May 2015
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of utomilumab in solid tumor, sponsored by Pfizer. Primary endpoint: Dose Limiting Toxicities. Started May 2015; status: terminated.
02
Drugs
utomilumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02444793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02444793.